Drug Index

Lanadelumab

 
print

Mechanism :

Human monoclonal antibody (IgG1/K-light chain) that binds plasma kallikrein and inhibits its proteolytic activity, controlling excess bradykinin generation in patients with hereditary angioedema.


Indication :

• Prophylaxis of hereditary angioedema


Contraindications :

No contraindications.


Dosing :

Prophylaxis of hereditary angioedema:

Children ≥12 years of age and adolescents:

Subcutaneous:

Initial: 300 mg every 2 weeks; dosing every 4 weeks may be considered in patients well-controlled (e.g., attack free) for >6 months.


Adverse Effect :

Headache, antibody development, injection site reactions, myalgia, upper respiratory tract infections, dizziness, skin rash, diarrhea, hypersensitivity.


Interaction :

No known significant interactions.


07/15/2019 06:31:21 Lanadelumab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0